STUDresearch · Peptide
Klotho
Also known as
alpha-Klotho · s-Klotho · Klotho protein
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
IM / SubQ
Longevity / cellular
Systemic biology for native α-Klotho; gray products may be antibodies, fragments or modified proteins, so identity and distribution cannot be assumed.
What people say
α-Klotho is a large membrane glycoprotein with a predominant shed soluble form, not one short peptide; reported gray products were described inconsistently as MAB, α-KlothoLR or binding-modified material.
Doses people talk about
These are unverified gray-product reports, not native α-Klotho dose finding. Only the IM account states peptide mass, and the names MAB, α-KlothoLR and binding-modified product may refer to materially different constructs.
How it may feel
One 10 mcg IM poster described an unusual clear, emotionally stable state for about six hours and initially worse sleep, then later claimed improved cognition, mood and sleep; a separate one-dose SC commenter reported nothing dramatic but did not state peptide mass.
Repeated IM report10 mcg IM per vial every 2 weeks
One poster described this schedule and supplied acute plus four- and five-week updates; product composition was not independently verified.
Half-life & effect duration
- Half-life in the body
- Gray-market productsNo product-specific settled estimate
- Felt duration people report
- One injected accountAltered state for about 6 hours, then 2 nights of worse sleep
- Later updatesBetter mood or cognition at 4 weeks and later better sleep
- Other accountNothing dramatic
Cycles people discuss
The clearest reviewed schedule was one 10 mcg IM vial every two weeks, with only one amount-unspecified SC use in another account. This is sparse product-specific reporting, not an established cycle.
Timing
The discussion is intermittent rather than a settled daily routine: one IM-product account described use every two weeks. Differently described products and uncertain identity prevent that account from establishing a general Klotho schedule.
Stacks
The main user repeatedly changed or stopped other neuroactive agents, so later mood, sleep and cognition claims cannot be cleanly attributed to the reported Klotho product.
Watch for
Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No product-verified human parent half-life was established for the gray products described in the reviewed community thread.
α-Klotho literature distinguishes a roughly 135 kDa membrane protein, a predominant roughly 130 kDa shed form and engineered constructs; the thread instead used conflicting antibody, receptor-ligand and binding-modified labels.
The formal review does not identify the reported products, and the user thread provides no assay, batch verification or human concentration-time data.
- Exploiting the neuroprotective effects of α-klotho to tackle ageing- and neurodegeneration-related cognitive dysfunction (opens in a new tab)Molecular properties section: 135 kDa transmembrane α-Klotho, predominant 130 kDa shed soluble form, KL1/KL2 processing and distinct proposed secreted forms.Narrative review focused on molecular biology and therapeutic potential; it does not characterize the products in the community reports or provide their human PK.
- Reddit r/BioLongevityLabs — Share your Klotho results (opens in a new tab)Original post and updates: 10 mcg IM per vial every two weeks, about six hours of acute subjective change, two nights of worse sleep, then four- and five-week claims; comments include one SQ use with peptide amount unstated and conflicting MAB/α-KlothoLR/binding-peptide identity descriptions.Unverified products and identities, anonymous self-selection, changing co-use, subjective outcomes and no human exposure measurements.
Felt duration people report
One 10 mcg IM poster described an acute altered but emotionally stable state for about six hours, followed by two nights of worse sleep; later updates reversed the sleep direction.
The same poster later claimed improved mood and cognition at four weeks and improved sleep by a later update, while a separate amount-unspecified SC user reported nothing dramatic.
One evolving anonymous report, changing co-use, no blinded comparator, conflicting product labels and a separate amount-unspecified SC account cannot establish prevalence or a general duration.
- Reddit r/BioLongevityLabs — Share your Klotho results (opens in a new tab)Original post and updates: 10 mcg IM per vial every two weeks, about six hours of acute subjective change, two nights of worse sleep, then four- and five-week claims; comments include one SQ use with peptide amount unstated and conflicting MAB/α-KlothoLR/binding-peptide identity descriptions.Unverified products and identities, anonymous self-selection, changing co-use, subjective outcomes and no human exposure measurements.
What people say
- Healthspan narrative: Klotho is discussed for aging markers, energy, or recovery more than acute gym pumps. forum
- Slow endpoints: Users often run months, not days, before claiming anything — and still confabulate. anecdote
- Stack noise: Frequently combined with multi-agent longevity stacks that destroy attribution. forum
- Preclinical cognition/aging: Rich animal literature. animal
- Human biomarker talk: Soluble klotho levels discussed as aging markers. trial
Doses people talk about
- Reported gray-product evidence: One Reddit poster described a 10 mcg IM vial every two weeks. A separate commenter described one SC dose but did not state peptide mass; the thread variously called products “MAB,” α-KlothoLR, or binding-modified, so these do not establish native α-Klotho dosing. forum
- Frequency: experimental intermittent talk more than validated daily use. forum
- Honesty: protein identity and purity risk dominate over dose math. forum
- Framing: α-Klotho longevity research interest. forum
How it may feel
- One 10 mcg IM report: The poster described an altered but emotionally stable state for about six hours and worse sleep for two nights; four- and five-week updates later described improved mood/cognition and eventually improved sleep. One evolving account cannot establish a typical course. forum
- Chronic biology: Not an acute party nootropic. forum
- Day 1: Most people notice logistics (route, sting, GI) more than a “miracle” effect from Klotho. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
Cycles people discuss
- No standard cycle: The reviewed thread described one 10 mcg IM vial every two weeks and a separate SC use with peptide amount unstated; neither establishes a validated human schedule for the claimed products. forum
- Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- No transferable human PK: Native α-Klotho, recombinant constructs, antibodies, and gray-market binding-modified products are not interchangeable; no product-verified human half-life was established for the reported gray products. trialforum
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Published PK: Where human PK exists it should override forum half-life memes for Klotho. trial
More on what it is
- Evidence honesty: Gene/protein biology is deep; injectable consumer products are poorly standardized. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Klotho, not proof it works for you. forum
- What it is: α-Klotho is a large membrane glycoprotein (~135 kDa) with a predominant shed soluble form (~130 kDa), not one short peptide. Gray-market “Klotho” products may describe different constructs. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Longevity stacks marketing: community forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Unknown impurities / immune reactions: community forum
- General caution: Research chemical and compounded sources vary; adverse events may be under-reported. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.